Immunofluorescent analysis of Mesothelioma in MCF-7 cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a Mesothelioma monoclonal antibody (Product # MA2-310) at a dilution of 1:20 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody (Product # 35503). Mesothelioma staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Mesothelioma cell line SPC111.|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||2-5 µg/ml|
|Immunohistochemistry (IHC)||2-5 µg/ml|
|Radioimmune Assays (RIA)||Assay dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA2-310 detects a surface membrane glycoprotein preferentially expressed on normal and malignant mesothelial cells from human tissues. This antibody does not detect most lung adenocarcinoma cell lines, or well and moderately differentiated pulmonary adenocarcinomas.
MA2-310 has been successfully used in indirect immunofluorescence, immunocytochemistry, immunohistochemistry and solid-phase radioimmunoassay procedures. This antibody does not react in Western blot procedures. Immunohistochemical staining of sarcomatoid mesotheliomas with MA2-310 results in intense staining of mesothelial cells.
MA2-310 will not react with formalin-fixed, or alcohol-fixed, paraffin embedded tissues. Use of frozen, acetone fixed sections or cell suspensions is recommended.
The MA2-310 antigen is mesothelioma cell line SPC111.
Reconstitute with PBS.
This monoclonal antibody was generated by the immunization of mice with the mesothelioma cell line SPC111. It has been reported that this antibody reacts with a 200 kDa surface membrane glycoprotein preferentially expressed on normal and malignant mesothelial cells, but does not react with most lung adenocarcinoma cell lines, or well and moderately differentiated pulmonary adenocarcinomas. In the two studies cited below, this antibody was reactive with all of the mesotheliomas examined, with 50%-99% of cells of both pleural and peritoneal mesotheliomas stained. Literature reports have indicated that the antibody does not bind with many common breast (MCF-7, T47D, ZR75-1, BT20, SJC38), ovarian (OVCA429, OVCA432, OVCA434), colon (SW480, SW620, CX1, WIDR, Co112), and renal-cell (FOHN, ZNH1) carcinoma cell lines, nor with several leukemia (K562, U937, CEM) or fibroblast (WI38, R2F) cell lines. Some reactivity has been reported with some pulmonary tumors of squamous-cell and small-cell carcinoma origin, adenocarcinoma of the breast, and ovary, and gastrointestinal adenocarcinomas. Also, melanomas and poorly differentiated pulmonary adenocarcinoma tumors have reacted with this antibody. The user is strongly encouraged to review the cited literature concerning the reported reactivity of this antibody.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer.
MA2-310 was used in flow cytometry to develop modification strategy for increasing the cellular uptake of porous silica microparticles
|Cheng K,Blumen SR,MacPherson MB,Steinbacher JL,Mossman BT,Landry CC||ACS applied materials and interfaces (2:2489)||2010|
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
MA2-310 was used in immunohistochemistry to investigate the possible application of ME1 in distinguishing different tumors of the pleura and peritoneum
|O'Hara CJ,Corson JM,Pinkus GS,Stahel RA||The American journal of pathology (136:421)||1990|